are winners!

Top News

Martinsried/Munich (09.09.2019) - 'iM-TCRs' enable controllable cytotoxicity of tumor-specific TCR-T cells to potentially tune safety and efficacy according to clinical needs  Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announces that Dr. Slavoljub Milosevic, Vice President of Technology and Innovation at Medigene AG, will be presenting "iM-TCR (inducible Medigene TCR): Controlled cytotoxicity of tumor-specific TCR-modified T cells with improved avidity through control of TCR surface expression" at the CAR-TCR Summit 2019 in ... [ more ]